Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2006

01-10-2006 | Erratum

Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

Authors: Elisabetta Munzone, Giuseppe Curigliano, Andrea Rocca, Giuseppina Bonizzi, Giuseppe Renne, Aron Goldhirsch, Franco Nolè

Published in: Breast Cancer Research | Issue 5/2006

Login to get access

Excerpt

It has been brought to our attention that some paragraphs in the Introduction and Discussion of our recent research article [1] show close similarities to paragraphs in recent publications by Oh et al. [2] and Holloway et al. [3]. While these publications were referenced elsewhere in our paper, the paragraphs which show similarities were not specifically referenced. …
Literature
1.
Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research. 2006, 8: R4-10.1186/bcr1366.CrossRefPubMed
2.
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol. 2001, 15: 1344-1359. 10.1210/me.15.8.1344.PubMed
3.
Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B. Mol Endocrinol. 2004, 18: 1396-1410. 10.1210/me.2004-0048.CrossRefPubMed
Metadata
Title
Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
Authors
Elisabetta Munzone
Giuseppe Curigliano
Andrea Rocca
Giuseppina Bonizzi
Giuseppe Renne
Aron Goldhirsch
Franco Nolè
Publication date
01-10-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1606

Other articles of this Issue 5/2006

Breast Cancer Research 5/2006 Go to the issue

Review

High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?

Research article

Plasma levels of leptin and mammographic density among postmenopausal women: a cross-sectional study

Research article

Classification of ductal carcinoma in situ by gene expression profiling

Commentary

Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis

Research article

A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

Commentary

Recent translational research: circulating tumor cells in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits